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Previewsmutation in the Crygc gene responsible
for causing cataracts was achieved by
the CRISPR/Cas9 system in mouse zy-
gotes and persisted in the progeny of
treated mice (Wu et al., 2013).
The second strategy would be to use
CRISPR/Cas9 technology to treat DMD
postnatally. This approach has the advan-
tage of applicability to all DMD patients,
regardless ofwhether themutationwas in-
herited or spontaneous. However, the
challenges of mosaicism, off-target ef-
fects, and immunogenicity would remain.
In addition, an efficient mechanism to
deliver the Cas9/guide RNA/template to
patients requires development, and this
is an almost completely unexplored
issue in adult mammals. Recent findings
showed that successful gene editing with
Cas9 could be achieved in hepatocytes
after intravascular injections of Cas9/
guide RNA/template into mice carrying a
mutation for fumarylacetoacetate hydro-
lase, which causes a fatal liver disease
(Yin et al., 2014). That finding suggeststhat postnatal genome editing for DMD
may also hold promise for functional re-
covery. Although muscle fibers are post-
mitotic and lack proteins required for
homologous recombination andare there-
fore refractory to HDR-mediated correc-
tion (Hsu et al., 2014), a population ofmus-
cle stem cells (satellite cells) that reside in
mature skeletal muscle are viable targets
for Cas9-mediated gene editing.
The exciting findings and clever exper-
imental design of Dr. Olson and his col-
leagues have illuminated a path for
correction of dystrophin mutations not
only in somatic cells to alleviate the dis-
ease in individuals, but also for correction
in the germline, which could feasibly elim-
inate the disease in the progeny, though
the road to clinical application may be
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Central MC4R pathways are well established as integrators of peripheral signals in the control of energy
balance. In this issue, Panaro et al. (2014) identify thatMC4Rs expressed on intestinal enteroendocrine L cells
regulate PYY and GLP-1 secretion, two gut hormones implicated in the regulation of energy and glucose
homeostasis.Feeding bouts are regulated by complex,
integrated neural and endocrine networks
in a process that attempts to optimize use
of nutrient availability in the context of
changing energy requirements. Hormonal
signals of ‘‘long-term’’ energy storage,
such as the adipokine leptin, act centrally
to modulate food intake (Morton et al.,2014). Feeding behavior is also modu-
lated centrally by an array of gut-derived
hormones that either promote initiation
(orexigenic) or termination (anorexigenic)
of feeding, thus serving as ‘‘short-term’’
signals of energy availability and regula-
tors of meal size (Morton et al., 2014).
For example, secretion of the orexigenichormone ghrelin from gastric mucosal
endocrine cells progressively increases
in the absence of nutrients. In contrast,
enteroendocrine L cells release the
anorexigenic hormones peptide YY (PYY)
and glucagon-like peptide-1 (GLP-1) in
response to nutrient stimulation. These
‘‘short- and long-term’’ energy signalsDecember 2, 2014 ª2014 Elsevier Inc. 929
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Previewsmodulate neuronal activity of hypotha-
lamic and brainstem nuclei, midbrain
reward areas, and higher cortical regions,
leading to integrated regulation of feeding
behavior (Morton et al., 2014).
Centralmelanocortin-4 receptor (MC4R)
circuits are recognized as key integrators
of ‘‘long-term’’ energy signals within the
neural networks that regulate energy
homeostasis (Girardet and Butler, 2014;
Morton et al., 2014). Fine-tuning of the
MC4R system has evolved to include
the presence of (1) two distinct endo-
genous agonists (a-MSH and ACTH), (2)
an endogenous inverse agonist (AGRP),
and (3) a regulatory accessory protein
(MRAP2). Central MC4R activation pro-
motes satiety, reduces insulin secretion,
increases insulin sensitivity, and in-
creases energy expenditure (Girardet
and Butler, 2014). MC4R haploinsuffi-
ciency, the most common monogenic
cause of severe obesity in humans,
results in hyperphagia and hyperinsuline-
mia, findings that are grossly recapitu-
lated in the Mc4r null mouse and that
precede weight gain (Girardet and Butler,
2014). MC4Rs are widely expressed
in the brain and have been identified in
around 150 brain nuclei. Knockout re-
expression studies indicate that MC4Rs
in the forebrain, including the paraven-
tricular nucleus of the hypothalamus
and the amygdala, regulate feeding, while
MC4Rs in preganglionic autonomic neu-
rons regulate body fat content, energy
expenditure, and glucose homeostasis
(Girardet and Butler, 2014). Importantly,
MC4Rs in the dorsomedial nucleus in
the brainstem regulate gastrointestinal
(GI) function, including meal size, indi-
rectly via parasympathetic vagal efferent
nerves. Recently, functional MC4R ex-
pression in gastric ghrelin cells was iden-
tified, although its physiological relevance
remains unclear (Engelstoft et al., 2013).
In a new study, Panaro and colleagues
(2014) now provide convincing evidence
for a direct physiological role of MC4R
expressed on enteroendocrine L cells in
regulating GI function and enhancing
secretion of anorexigenic gut peptides.
The study culminates with the finding
that an enteroendocrine MC4R system
acts as a regulator of PYY and GLP-1
release in vivo.
In a series of intestinal MC4R char-
acterization experiments incorporating
fluorescence-assisted cell sorting and930 Cell Metabolism 20, December 2, 2014 ªimmunohistochemistry, Panaro and co-
workers (2014) identified that intestinal
mucosal MC4R expression is predomi-
nantly localized to enteroendocrine L
cells. The functionality of L cell MC4R
was established using multiple MC4R
ligands, across an array of models,
including in isolated intestinal cell pre-
parations, in a representative enteroendo-
crine cell line, in mucosa from mouse
intestine or human colon, and in mice
in vivo.
Importantly, functional studies using
the model of L cell regulation of epithelial
chloride secretion also established that
the effects of L cell MC4R activation are:
(1) independent of submucosal neuronal
stimulation (tetrodotoxin insensitive), (2)
epithelial Y1 receptor dependent (sug-
gestive of a PYY paracrine effect), and
(3) mediated by MC4R stimulation on the
basolateral but not lumenal membrane
of L cells (suggestive of a humoral MC4R
ligand). Further in vivo rodent studies
confirmed that L cell, but not central,
MC4R activation accounts for MC4R
agonist effects on PYY secretion and
that this enhanced PYY secretion is suffi-
cient to slow colonic motility.
This comprehensive body of work has
the potential to impact upon multiple
overlapping research fields. In the field
of bariatric surgery, enhanced post-
operative secretion of L cell products is
implicated in mediating the beneficial
metabolic effects of specific bariatric
operations such as Roux-en-Y gastric
bypass (RYGBP) (Madsbad et al., 2014)
(Figure 1). The work by Panaro et al.
(2014) could explain why carriers of a
MC4R variant (I251L), which increases
basal MC4R activity, experience signifi-
cantly greater weight loss after RYGBP
compared with noncarriers or carriers of
other MC4R variants (Mirshahi et al.,
2011). In the setting of enhanced PYY/
GLP-1 secretion post-RYGBP, increased
basal MC4R activity could further
augment this L cell response, promoting
greater reductions in food intake in I251L
carriers (Figure 1). Interestingly, MC4R
signaling is critical for the sustained re-
ductions in food intake and weight loss
engendered by RYGBP, as demonstrated
by studies undertaken in Mc4r null mice
(Hatoum et al., 2012). These studies
suggest either that non-MC4R-mediated
mechanisms by which RYGBP affects
energy balance are not powerful enough2014 Elsevier Inc.to overcome complete absence of MC4R
signaling or that the MC4R system is
intrinsic to the biological response to
RYGBP (Figure 1). However, a study em-
ploying intracerebroventricular adminis-
tration of a specific MC4R antagonist
in RYGBP and sham-operated rats
demonstrated that, while central MC4R
blockade led to doubling of food intake
and weight regain, the RYGBP-driven
reduction in meal size was unaffected
(Mumphrey et al., 2014). These findings
suggested that peripheral MC4R path-
ways govern meal size, a concept now
supported by the work of Panaro et al.
(2014).
A further intriguing corollary of the study
is the potential for host-gut microbiota
interactions impacting on the enteroen-
docrine MC4R system. The dynamic be-
tween ‘‘healthy’’ and ‘‘harmful’’ micro-
biota is now thought to regulate multiple
host metabolic effects, although the
mechanisms underlying these effects
remain to be fully elucidated. A recent
study demonstrated evidence formolecu-
lar mimicry involving a gut bacterial ClpB
heat-shock protein and theMC4R agonist
a-MSH (Tennoune et al., 2014). While the
study (Tennoune et al., 2014) focused on
the relevance of the findings for patients
with eating disorders, the possibility of
local modulation of enteroendocrine
MC4R function by a microbiota-derived
a-MSHmimetic (Figure 1) now has poten-
tially far-reaching implications in the
fields of type 2 diabetes, obesity, and
irritable bowel syndrome.
Finally, the study by Panaro and col-
leagues poses the question of whether
enteric neurons, originating outside of
the brain, could directly regulate enter-
oendocrine cells via the MC4R system.
Exciting research describing neuronal-
like features and direct innervation
of enteroendocrine cells has recently
emerged (Boho´rquez et al., 2014). Enter-
oendocrine cells exhibit a prominent
basal cytoplasmic process, termed a
‘‘neuropod,’’ containing neurofilaments,
which are the typical structural pro-
teins of axons. These ‘‘neuropods’’ are
escorted by enteric glia, and their devel-
opment is enhanced by glial-derived
neurotrophic factors. Our understanding
of neural interactions with the enteroen-
docrine system is thus rapidly advancing.
The work by Panaro et al. (2014) firmly
places the enteroendocrine MC4R
Figure 1. A Schematic Overview of Integration of Central and Enteroendocrine MC4R Pathways during Dieting and after RYGBP
In Roux-en-Y gastric bypass (RYGBP), a small gastric pouch is created and connected with the mid-jejunum, thereby allowing nutrients to bypass the majority
of the stomach, the duodenum, and the proximal jejunum. Reductions in circulating leptin occur with dieting and after RYGBP and lead to lower hypothalamic/
brainstem a-MSH (a-melanocyte stimulating hormone) production from pro-opiomelancortin (POMC), resulting in reduced activation of central MC4R, thus
promoting increased appetite. Circulating adrenocorticotrphic hormone (ACTH), a POMC product secreted from the pituitary gland, is increased after dieting
but not after RYGBP. Long-term gut hormonal adaptations occur after dieting, including increased secretion of the orexigenic hormone ghrelin and reduced
secretion of the anorexigenic L cell products peptide YY (PYY) and glucagon-like peptide-1 (GLP-1). MC4R activation in gastric ghrelin cells stimulates ghrelin
secretion. The release of PYY and GLP-1 secretion is markedly enhanced after RYGBP, due to expedited exposure of distal intestinal L cells to nutrients. GLP-1
(directly) and PYY (indirectly) act on POMC-expressing neurons, increasing central a-MSH production and reducing appetite. Panaro et al. (2014) show that L cell
MC4R activation enhances GLP-1 and PYY secretion. Candidate physiologic ligands for L cell MC4R include a-MSH, ACTH, and autoantibodies produced in
response to gut microbiota-derived ClpB heat shock protein. Enhanced L cell secretion of PYY and/or GLP-1 could promote greater reductions in appetite in
carriers of the I251L MC4R allele compared to noncarriers among patients undergoing RYGBP. Dashed black lines indicate a relatively lower level of signaling.
Solid red lines indicate a relatively higher level of signaling.
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Previewspathway at the center of an increasingly
more complex model of energy balance
regulation (Figure 1).
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